Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Moleculin Biotech says common stock to resume trading on Nasdaq on May 28 » 17:55
05/27/20
05/27
17:55
05/27/20
17:55
MBRX

Moleculin Biotech

$1.06 /

+ (+0.00%)

Moleculin Biotech, Inc…

Moleculin Biotech, Inc announced that it has received notification from Nasdaq that trading in the company's common stock will resume on Thursday, May 28, 2020.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer
Hot Stocks
Moleculin Biotech engages ImQuest, IITRI to support IND application of WP1122 » 16:50
05/27/20
05/27
16:50
05/27/20
16:50
MBRX

Moleculin Biotech

$1.06 /

+ (+0.00%)

In order to properly…

In order to properly support the company's planned IND application, it has engaged ImQuest BioSciences and the Illinois Institute of Technology Research Institute, two organizations focused on supplying the kind of contract research support required for an IND submission. While IITRI is initially focused on preclinical toxicology testing to help determine whether WP1122 can be considered safe for testing in humans, ImQuest is focused on supporting the scientific rationale behind proposing WP1122 as a possible treatment for COVID-19. On April 7, Moleculin contracted with ImQuest for two rounds of preclinical assessment of the potential for WP1122 to address COVID-19. The first step was to demonstrate whether or not the improved pharmacology of WP1122 gave it a greater therapeutic window than 2-DG, a compound which was shown to stop replication of SARS-CoV-2 by an independent research team at the Goethe-University of Frankfurt in a preprint of a research article and also was previously shown to display antiviral activities in other viruses. This first ImQuest step was done with a cell viability assay comparing inhibition of virus-induced cytopathic effects of 2-DG and WP1122 head-to-head in a human cell line infected with a coronavirus. The second round was to demonstrate the ability of WP1122 to inhibit coronavirus production in mammalian cell culture. This was done using a virus yield reduction assay. The testing done by ImQuest was performed on a surrogate of SARS-CoV-2 called Human coronavirus strain 229E because it was a validated assay immediately available at ImQuest. Moleculin's scientific team and ImQuest consider HCoV-229E to be an appropriate model for SARS-CoV-2 in particular because one of the primary theoretical mechanisms of action for both 2-DG and WP1122 is alteration of the glycoprotein/glycan structures (spikes) that form on the outside shielding of the virus, and the glycoprotein/glycan spikes present on HCoV-229E play a similar function in the viral lifecycle to those on SARS-CoV-2. As well, the other primary MOA of 2-DG/WP1122 is the inhibition of glycolysis and the HCoV-229E surrogate has a similar dependence on glucose/mannose metabolism. Although these in vitro results should not be considered conclusive or indicative of what will happen in vivo, the initial results received on May 4, 2020 show that both 2-DG and WP1122 have an antiviral effect on HCoV-229E. WP1122 displayed a greater therapeutic index than 2-DG, while the virus yield reduction assay demonstrated a 5 to 10-fold inhibition of coronavirus production by WP1122 and 2-DG when compared to untreated virus control. Out of an abundance of caution, the company requested ImQuest repeat their tests to provide additional confidence in their findings, and, as such, the company cautions readers not to rely on these initial results. In addition to having ImQuest repeat their tests, the company is arranging for additional in vitro testing to include additional human cell lines and the use of a validated SARS-CoV-2 assay, as well as testing against other pathogenic viruses, all with the intent of increasing the strength of the basic scientific rationale.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer
Hot Stocks
Moleculin Biotech: FDA grants request for Pre-IND Meeting on WP1122 » 16:11
05/27/20
05/27
16:11
05/27/20
16:11
MBRX

Moleculin Biotech

$1.06 /

+ (+0.00%)

Moleculin Biotech…

Moleculin Biotech announced that the U.S. FDA has granted the company's request for a Pre-IND Meeting to provide guidance regarding the company's plan to study its drug candidate, WP1122, in a clinical trial for patients with COVID-19. In addition, Moleculin provided a general update on its WP1122 development efforts. The company said, "We estimate that we should be able to submit our IND application in the second half of this year. More specific timing will depend upon the guidance we receive from our Pre-IND Meeting with the FDA."

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer
Over a week ago
Hot Stocks
Moleculin Biotech stock halted by Nasdaq pending additional information » 07:32
05/18/20
05/18
07:32
05/18/20
07:32
MBRX

Moleculin Biotech

$1.06 /

+ (+0.00%)

Moleculin Biotech…

Moleculin Biotech announced that pending the receipt of additional information from the company, Nasdaq has halted the trading in the company's common stock. The company is actively working with the staff of Nasdaq to provide it with all requested information, and hopes to begin trading as soon as possible.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer
Hot Stocks
Moleculin Biotech provides additional comments on trading suspension » 07:49
05/11/20
05/11
07:49
05/11/20
07:49
MBRX

Moleculin Biotech

$1.06 /

+ (+0.00%)

Moleculin Biotech…

Moleculin Biotech announced that since the May 1 temporary suspension by the Securities and Exchange Commission of trading in the securities of Moleculin Biotech, additional information has come to the company's attention regarding claims disseminated by third parties. The company said, "Moleculin has learned that certain third parties made claims and distributed information during the period between March 20th, 2020 to May 5th, 2020 about the potential efficacy and clinical development of WP1122 with respect to coronavirus. The Company neither solicited, had advance knowledge of, nor played any role in the preparation of such information, claims or statements. Moleculin encourages all investors and persons of interest to look at the Company's releases and filings regarding the potential development of WP1122 for the treatment of COVID-19. The SEC's suspension of trading Moleculin stock is scheduled to terminate at 11:59 p.m. ET on May 15th, 2020."

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer
Hot Stocks
Moleculin Biotech placed on trading suspension until end of May 15th » 19:54
05/04/20
05/04
19:54
05/04/20
19:54
MBRX

Moleculin Biotech

$1.06 /

+ (+0.00%)

Moleculin Biotech…

Moleculin Biotech announced securities of the company have been placed in a temporary trading halt following notification by the US Securities and Exchange Commission. On May 1st, 2020, the SEC temporary suspended, pursuant to Section 12(k) of the Securities Exchange Act of 1934, trading in the securities of Moleculin Biotech at 9:30 a.m. ET on May 4th, 2020 due to the Commission's questions regarding the accuracy of recent information distributed by the Company. Those questions relate to, among other things, statements made by Moleculin and others, in its Form 10-K filed with the SEC on March 19th, in press releases on March 20th and April 8th, and in other statements on March 19th, March 20th, and April 16th concerning the Company's business, including the status of development of WP1122 for potential application to COVID-19, and the Company's ability to expedite regulatory approval of any such treatment. The suspension will terminate at 11:59 p.m. ET on May 15th, 2020. Moleculin looks forward to responding to the SEC and working with the Commission to resolve these questions in a timely manner.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.06 /

+ (+0.00%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer
Hot Stocks
Moleculin Biotech approved to accelerate European clinical trial » 07:32
04/28/20
04/28
07:32
04/28/20
07:32
MBRX

Moleculin Biotech

$1.16 /

+0.025 (+2.21%)

Moleculin Biotech…

Moleculin Biotech announced that it is now authorized by the Polish Department of Registration of Medicinal Products known as URPL to accelerate the Phase 1 dose escalation portion of its clinical trial of Annamycin for the treatment of acute myeloid leukemia. The URPL has allowed an amendment to the Annamycin clinical trial protocol, which among other things, includes an increase in the dose escalation increment between cohorts from 30 mg/m to 60 mg/m. The clinical trial is currently recruiting for the 240 mg/m cohort, so this amendment allows the next cohort to increase to 300 mg/m, assuming all requirements for safety are met with the 240 mg/m cohort.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.16 /

+0.025 (+2.21%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer
Over a month ago
Hot Stocks
WPD, CNS announce additional coronavirus testing on WP1122 » 07:16
04/21/20
04/21
07:16
04/21/20
07:16
CNSP

CNS Pharmaceuticals

$3.19 /

+0.1 (+3.24%)

, MBRX

Moleculin Biotech

$1.19 /

-0.005 (-0.42%)

WPD Pharmaceuticals along…

WPD Pharmaceuticals along with its development partner CNS Pharmaceuticals, Inc. (CNSP), announce that ImQuest Biosciences has been engaged to expand in vitro and in vivo testing of WP1122, a drug candidate for the treatment of COVID-19. The agreement with ImQuest Biosciences was entered into by WPD's license partner Moleculin Biotech, Inc. (MBRX) to expand testing of WP1122 as a potential treatment for the Coronavirus. WPD is not making any express or implied claims that this new partnership may eliminate, cure or contain the Covid-19 at this time. ImQuest BioSciences is a preclinical CRO that provides expert services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases. ImQuest has developed a robust platform to identify and support the development of therapeutic products to inhibit and prevent coronavirus infection. These preclinical research services are part of the ImQuestSUCCESS Platform and include compound screening to define compound efficacy and drug target validation to define the mechanism of action and toxicity of pharmaceutical products, as well as evaluation of the potential of products to induce resistance and the impact of combination antiviral therapy.

ShowHide Related Items >><<
CNSP CNS Pharmaceuticals
$3.19 /

+0.1 (+3.24%)

12/04/19 Benchmark
CNS Pharmaceuticals initiated with a Speculative Buy at Benchmark
MBRX Moleculin Biotech
$1.19 /

-0.005 (-0.42%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer
Hot Stocks
Moleculin Biotech signs agreement with ImQuest Biosciences » 07:41
04/20/20
04/20
07:41
04/20/20
07:41
MBRX

Moleculin Biotech

$1.20 /

-0.255 (-17.53%)

Moleculin Biotech…

Moleculin Biotech announced that it has entered into an agreement with ImQuest Biosciences to expand in vitro and in vivo testing of WP1122, Moleculin's lead drug candidate for the treatment of COVID-19. The announcement follows on the heels of the discovery by researchers at the Goethe University in Frankfurt that 2 deoxy-D-glucose inhibited SARS-CoV-2 replication in susceptible cell lines. ImQuest BioSciences is a preclinical CRO that provides expert services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.20 /

-0.255 (-17.53%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer
Conference/Events
Moleculin Biotech to hold a conference call » 15:55
04/16/20
04/16
15:55
04/16/20
15:55
MBRX

Moleculin Biotech

$1.41 /

+0.13 (+10.16%)

Chairman & CEO Klemp…

Chairman & CEO Klemp discusses the significance of the recent discovery that the active compound in WP1122 has been shown to reduce replication of SARS-CoV-2 by 100% on a conference call to be held on April 16 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.41 /

+0.13 (+10.16%)

04/08/20 Roth Capital
Moleculin can expedite COVID candidate amid less restrictions, says Roth Capital
10/17/19 Oppenheimer
Moleculin Biotech initiated with an Outperform at Oppenheimer

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.